Stay informed with the latest provider updates, pricing changes, and industry news in the GLP-1 medication space.
The GLP-1 market hits an inflection point — FDA approves higher-dose Wegovy 7.2mg, Hims settles with Novo and becomes an authorized seller, Zepbound Medicare coverage starts at $50/mo, and Lilly's oral pill orforglipron faces its FDA decision date. Here's what it means for your provider choices.
Foundayo (orforglipron) is now FDA-approved for weight loss — the only GLP-1 pill with no food or water restrictions. Here's what it costs, how it compares to Wegovy and Zepbound, and when insurance will cover it.
The GLP-1 market is shifting dramatically - Novo Nordisk announces 50% price cuts for 2027, Hims faces lawsuits and SEC investigation, TrumpRx launches, and Medicare coverage nears. Here's what it means for your provider choices.
A comprehensive roundup of significant changes across GLP-1 providers this month, including partnership shake-ups, pricing updates, and medication availability changes.
Pricing changes, new providers, and regulatory updates - we track it all so you can make informed decisions about your GLP-1 treatment.
Compare GLP-1 providers and find the best option for your needs and budget.